Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...] …
Category: Pharma Industry
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...] …
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...] …
Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...] …
Kalderos, the drug industry vendor behind two 340B claims data submission platforms which support 340B rebates, will file an updated [...] …
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year, [...] …
Belgium pharmaceutical giant UCB is extending its 340B contract pharmacy restrictions to all federal grantees and adding new data submission [...] …
A New Jersey-based drugmaker announced this week that beginning in December, its 340B contract pharmacy restrictions will apply to Health [...] …